Abstract
The treatment of patients with schizophrenia who fail to respond to antipsychotic medications remains a challenge. Despite numerous attempts to establish effective somatic treatment approaches for this population, clozapine appears to be the only well established alternative. Depending upon trial duration and response criteria, between 30% and 60% of previously unresponsive patients appear to derive clinically significant benefit from clozapine. Clozapine also has important advantages in terms of its reduced propensity to produce extrapyramidal side-effects. Agranulocytosis remains an important risk, so strategies to improve the benefit-to-risk ratio should be explored. Issues such as trial duration, dosage, blood levels and predictors of response require additional study.
Publisher
Royal College of Psychiatrists
Subject
Psychiatry and Mental health
Reference36 articles.
1. Clozapine plasma levels and convulsions;Simpson;American Journal of Psychiatry,1978
2. The European experience with the use of clozapine;Naber;Hospital and Community Psychiatry,1990
3. Clozapine: an atypical antipsychotic agent;Ereshefsky;Clinical Pharmacology,1989
4. Biologic indices of heterogeneity in schizophrenia: Relationship to psychopathology and treatment outcome
5. Clozapine: guidelines for clinical management;Lieberman;Journal of Clinical Psychiatry,1989
Cited by
126 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献